One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...
News Medical on MSN11d
GLP-1 drugs may reduce surgery complications in patients with diabetesDrug companies began developing GLP-1 drugs to treat diabetes in the early 1990s, and the first of them reached clinics ...
McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback